Literature DB >> 23362877

Photoprotective effect of libanoridin isolated from Corydalis heterocarpa on UVB stressed human keratinocyte cells.

Byul-Nim Ahn1, Jung-Ae Kim, Chang-Suk Kong, Youngwan Seo, Se-Kwon Kim.   

Abstract

Ultraviolet-B (UVB) irradiation acts primarily on the epidermal basal cell layer of the skin, inducing harmful biological effects. In this study, we have investigated the effect of libanoridin isolated from Corydalis heterocarpa against UVB-induced damage in human keratinocyte (HaCaT) cells and the molecular mechanism underlying those effects. Treatment with libanoridin inhibited the cell cytotoxicity and LDH induced by UVB exposure at 40 mJ/cm(2). Additionally, expression levels of type IV collagenases (MMP-2, MMP-9) were decreased by libanoridin. Furthermore, MMP tissue inhibitors were enhanced followed by treatment with libanoridin. Moreover, UVB-induced activation of phosphorylation of three MAPKs such as JNK, ERK, p38 and AP-1 transcription factor were decreased by treatment with libanoridin. Our present study demonstrates that libanoridin has the abilities to inhibit UVB-induced cellular damage via ASK1-MAPK and AP-1 signalling pathways. Therefore, libanoridin may be used as an effective natural compound to prevent skin damage due to UVB exposure.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23362877     DOI: 10.1111/exd.12085

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  2 in total

1.  Impact on Autophagy and Ultraviolet B Induced Responses of Treatment with the MTOR Inhibitors Rapamycin, Everolimus, Torin 1, and pp242 in Human Keratinocytes.

Authors:  Song Xu; Li Li; Min Li; Mengli Zhang; Mei Ju; Xu Chen; Heng Gu
Journal:  Oxid Med Cell Longev       Date:  2017-03-16       Impact factor: 6.543

2.  Anti-Inflammatory Effect of ETAS®50 by Inhibiting Nuclear Factor-κB p65 Nuclear Import in Ultraviolet-B-Irradiated Normal Human Dermal Fibroblasts.

Authors:  Ken Shirato; Tomoko Koda; Jun Takanari; Takuya Sakurai; Junetsu Ogasawara; Kazuhiko Imaizumi; Hideki Ohno; Takako Kizaki
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-03       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.